Skip to main content
Jerry Spivak, MD, Hematology, Baltimore, MD

JerryLe PowSpivakMD

Hematology • Baltimore, MD

Professor of Medicine, Johns Hopkins University School of Medicine; Director, Center for the Chronic Myeloproliferative Disorders

Join to view full profile

Dr. Spivak is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Spivak's full profile

Already have an account?

Education & Training

  • Johns Hopkins University
    Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1969 - 1972
  • New York Presbyterian Hospital (Cornell Campus)
    New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1968 - 1969
  • Johns Hopkins University
    Johns Hopkins UniversityResidency, Internal Medicine, 1965 - 1966
  • Johns Hopkins University School of Medicine
    Johns Hopkins University School of MedicineInternship, Transitional Year, 1964 - 1965
  • Weill Cornell Medicine
    Weill Cornell MedicineClass of 1964

Certifications & Licensure

  • MD State Medical License
    MD State Medical License 1969 - 2025
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

  • America's Top Doctors Castle Connolly, 2002-2014
  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014
  • America's Top Doctors for Cancer Castle Connolly, 2005-2013
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Worse Outcomes in Males with MPN Are Associated with Qualitative and Quantitative Differences in Non-Driver Mutational Burden
    Jerry L. Spivak, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • The High Mobility Group A1 Chromatin Regulator Is Required for Pathologic Megakaryocyte Development and Progression to Myelofibrosis in JAK2V617F Murine Models
    Jerry L. Spivak, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • High Mobility Group A1 Chromatin Regulators: Key Epigenetic Switches and Therapeutic Targets Required for Leukemic Transformation in JAK2 Mutant MPN
    Jerry L. Spivak, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

  • High Mobility Group A1 Chromatin Remodeling Proteins Amplify Inflammatory Networks to Drive Leukemic Transformation in Chronic Myeloproliferative Neoplasia in Humans a... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Independent Association of Male Sex with Presentation and Clinical Outcomes in Myeloproliferative Neoplasms 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • COVID Vaccine Dystopia: A Manifesto Pt. 2 (By Dr. Joel S. Hirschhorn)
    COVID Vaccine Dystopia: A Manifesto Pt. 2 (By Dr. Joel S. Hirschhorn)December 2nd, 2021
  • Reader Responses: Is JAK2 Positivity Clinically Significant in This 28-Year-Old Patient with Budd-Chiari Syndrome?
    Reader Responses: Is JAK2 Positivity Clinically Significant in This 28-Year-Old Patient with Budd-Chiari Syndrome?September 1st, 2021
  • Covid-19 Injections: What the Officials Are Saying
    Covid-19 Injections: What the Officials Are SayingFebruary 11th, 2021
  • Join now to see all

External Links

Dr. Jerry Spivak, Dr. Jerry Spivak, MD, Dr. J Spivak, Dr. Jerry Le Pow Spivak